Abstract: AimsIn order for Chlamydia pneumoniae to play a causative role in chronic human disease, it would need to persist within infected tissue for extended periods of time. Current theory suggests that C pneumoniae may persist at the site of infection via an alternative replicative form, known as an aberrant body.MethodsA panel of C pneumoniae-specific antibodies upregulated by the aberrant body was used to probe tissue specimens from the coronary atheroma from 13 explanted hearts to identify patterns of reactivity in these tissues, as well as to determine the presence and prevalence of C pneumoniae aberrant bodies.ResultsSix of 13 patients had an ischaemic cardiomyopathy secondary to coronary atherosclerosis, while another six patients had an idiopathic, dilated cardiomyopathy. One additional patient, a young (24 years) woman with cardiomyopathy, had no history of atherosclerotic disease. Eleven patients were positive by immunohistochemistry with at least one antibody. Coronary arteries of the two other patients were negative by immunohistochemistry with all antibodies. One of these patients was the 24-yearold woman with grade I disease and no risk factors for coronary artery disease.ConclusionsThe protein antigens of persistent C pneumoniae infection found in the atheromatous lesions from patients in this study could potentially be used as markers to detect such infections and some may be virulence factors or immunogens specific to C pneumoniae, thus serving as target molecules for diagnostic use or therapeutic intervention. Methods: A panel of C. pneumoniae-specific antibodies up-regulated by the AB was used to probe tissue specimens from the coronary atheroma from 13 explanted hearts to identify patterns of reactivity in these tissues, as well as to determine the presence and prevalence of C.
 (Borel et al., 2006 (Borel et al., & 2008 
Introduction
Chlamydia pneumoniae is an obligate intracellular pathogen which causes acute and chronic respiratory infections in humans (1-4). Over the last decade, a significant amount of data have suggested a role for C. pneumoniae in chronic human disease, in particular, atherosclerosis;
however, a direct causal role remains to be established (5) . In order for C. pneumoniae to play a causative role in chronic human disease, it would need to persist within infected tissue for extended periods of time. One hypothesis suggests that C. pneumoniae persists at the site of infection via an alternative replicative form, known as an aberrant body (AB) defined as viable but noncultivable form of chlamydiae (6) . These ABs may represent the mechanism by which this organism persists and causes the chronic inflammatory-type infections characteristic of C.
pneumoniae, and other chlamydiae. Chlamydial ABs have been shown to exist, in vitro (7), and we have detected AB-like structures of C. suis in infected pigs (8) . We have also identified evidence of persistent C. pneumoniae in the atheroma of patients with coronary artery disease (CAD) by TissueMicroarray and
Immunogoldelectron (IMG) microscopy (9,10), however, these data were collected on archived specimens. Therefore, we conducted a prospective examination of human atheromatous tissue from explanted hearts of patients receiving heart transplants.
The objective of this study was to use a panel of C. pneumoniae-specific antibodies, the majority of which are reactive to antigens upregulated in the persistent state of the organism, to probe tissue specimens from the coronary arteries from explanted hearts to identify patterns of reactivity in these tissues, as well as to determine the presence and prevalence of C. pneumoniae
ABs. Antibodies directed against chlamydial proteins upregulated during the persistent stage in vitro (LPS/MOMP, GroEL and GroES) and suitable to screen atheromatous samples in vivo (9, 10) were applied in the present study. In addition, recently described antibodies (11, 12) against other chlamydial proteins such as incA, cpaf and HtrA were used to investigate coronary artery specimens. Immunohistochemistry examinations were complemented by a thourough investigation of adjacent coronary artery tissue specimens by histopathology, culture, PCR and 
Methods

Patients
Explanted hearts from 13 patients (IDL-01 to IDL-13) seeking heart transplantation were investigated. This study was approved by the University of Louisville Institutional Review 
Histopathology
At least two pieces of the left and right coronary arteries were collected from the excised tissue samples and immediately fixed in 4% buffered formalin. Each was routinely processed and stained with hematoxylin and eosin. Atheroma grading was performed by a cardiac pathologist and was assigned a Grade I through V occlusion score.
Antibodies
Antibodies directed against C. pneumoniae-specific proteins are shown in was selected for immunogold electron microscopy labeling.
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded sections were stained with the panel of primary antichlamydial-antibodies as in Table 1 and detection was performed with the Detection Kit (Dako ChemMate TM Detection Kit, Glostrup, Denmark) according to the manufacturer's instructions.
The optimal dilution for each antibody was previously determined on HEp-2 cell monolayers infected with C. pneumoniae for 72 hrs. 
Transmission electron microscopy (TEM)
Glutaraldehyde-fixed coronary artery specimens were post-fixed in osmium tetroxide and then embedded in epon. Appropriate areas for ultrastructural investigation were selected using semithin sections (1 µm) stained with toluidine blue (Fluka, Buchs SG, Switzerland). Ultra-thin sections (80 nm) for TEM were mounted on gold grids (Merck Eurolab AG, Dietlikon, Switzerland), contrasted with uranyl acetate dihydrate (Fluka) and lead citrate (lead nitrate and tri-natrium dihydrate; Merck Eurolab AG) and examined for the presence of chlamydial developmental stages in an electron microscope (Philips CM10).
Immunogold electron microscopy labeling (IMG)
For IMG labeling, sections were labeled with the primary antibody LPS/MOMP at a dilution of 1:500 at RT overnight. After washing with PBS/TBS buffer for 30 min, samples were incubated with a 18-nm colloidal gold-conjugated polyclonal IgG anti-rabbit secondary antibody (dilution 1:15) for 2 h. The sections were then washed for another 20 min, rinsed with deionized water, and contrasted as described (10) . Uninfected and infected (72h) HEp-2 cell pellets were used as negative and positive controls, respectively.
Culture
Culture was performed at two laboratories in HEp-2 cell monolayers using standard methods.
In brief, patient samples were mechanically disrupted and centrifuged at 1,000 x g onto sub-
confluent HEp-2 cell monolayers for 1h in serum free MEM-Eagles medium (Invitrogen, Carlsbad, CA, USA) in 24 well plates. Subsequently, MEM-eagles, containing 10% FBS and 2
! g/ml cycloheximide, was added. Following 72 h of incubation at 37°C, the entire contents of each well was harvested and sonicated for 5 min at 4°C. This was divided into two wells of a 24-well plate and inoculation was carried out as described above. Immunofluorescence microscopy was carried out on the contents of one well using the Pathfinder Chlamydia Culture
Confirmation System (BioRad, Hercules, CA, USA). The remaining well was passaged into two new wells after 72h of additional incubation.
DNA extraction and Polymerase chain reaction (PCR)
PCR was as performed at two separate laboratories. Prior to PCR, tissue specimens from coronary atheroma in M4 transport medium were processed for DNA extraction using a commercial DNA extraction kit (DNeasy Tissue kit; Qiagen, Hilden, Germany).
At one site, a real-time PCR was conducted on an ABI 7500 instrument (Applied Biosystems, Foster City, CA) using a modified version of the procedure of Everett et al (13). This 23S-based
Chlamydiaceae family-specific real-time PCR as described previously (14) At the second site, a real-time multiplex PCR with 3 probes that can detect C. trachomatis, C.
pneumoniae and C. psittaci was used (15).
Microimmunofluorescence (MIF)
Serum samples were collected immediately prior to heart transplantation from all patients.
Blood samples were centrifuged (3000 × g, 10 min) and sera were stored at -80 C prior to testing. IgG and IgM antibody titers were determined by MIF using commercial kits (Focus Diagnostics, Cypress, CA) according to manufacturer's instructions.
Western Blot
In a previous study (16), the serological response to novel C. pneumoniae antigens associated with persistent C. pneumoniae infections was characterized. According to these results, the molecular chaperone Hsp70 (DnaK), the RNA polymerase -chain (RpoA) and the hypothetical protein CpB0704 were found to be immunodominant and thus selected to test human sera from the 13 transplanted patients. Serum reactivity towards RpoA, DnaK and the hypothetical protein CpB0704 was analyzed as described previously (17). In brief, the recombinant proteins were separately applied to sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by electroblotting onto Bio Trace NT nitrocellulose membranes (Pall, Port Washington, NY, USA). The membranes were blocked using 5% nonfat dry milk, cut into strips with 4 mm width of which each was incubated with a serum sample of the 13 donors at a dilution of 1:1,000. After four subsequent washing steps, the strips were incubated with a peroxidase-conjugated rabbit anti-human IgG antibody (1:2,000 dilution, DakoCytomation) for 45 min followed by another four washing steps. Immunoreactive bands were visualized and quantified by enhanced chemiluminescence detection using a LAS-3000 imaging system (Fuji) and the AIDA software package (Raytest/Fuji). An intensity threshold of 1,000 counts above the background level was used as the cutoff.
Results
Detailed results of individual patients are shown in Table 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 pneumoniae, including AB (data not shown).
Culture and PCR for C. pneumoniae was negative in all 13 patients in both laboratories (data not shown).
All 13 patient sera were negative for IgM antibodies by MIF (data not shown). IgG titers were lower (n=2) or equal (n=2) to 1:64, or higher: 1:128 (n=1), 1:256 (n=7) and highest in patient IDL-08 (1:512). Western blot analysis of sera showed positive results for RpoA (n=3), DnaK (n=2) or both (n=6). Only three sera showed reactivity to the hypothetical protein CpB0704.
Discussion
Atheromatous tissues from patients with Grade III to V pathology demonstrated reactivity to antibodies to C. pneumoniae proteins that are upregulated in models of in vitro persistence. One young patient, who could conceivably be viewed as a "negative control" in this study, showed no reactivity to any of the serum antibodies tested. This patient was transplanted due to cardiomyopathy at a very young age and also had no risk factors for CAD. Eleven of the 12 other patients showed a variable degree of reactivity with one or more of the antibodies tested, indicating the presence of these antigens within the atherosclerotic lesions of these patients. By immunohistochemistry, antibodies against chlamydial proteins whose increased expression has been demonstrated in in vitro models of persistence (7), were applied to detect persistent infections. Antibodies against LPS/MOMP, GroEL and GroES were suitable to detect aberrant bodies of C. pneumoniae by IHC and IMG in two previous studies on archived material (9, 10) and similarly showed positive labeling in the majority of patients in the present study. By proteomic analyses, MOMP and heat shock proteins such as GroEL and GroES have been shown to be upregulated in various induced persistence models of C. pneumoniae (20,21) and these findings were confirmed by our study of coronary artery samples. A rigorous and labor-intensive examination by TEM and IMG failed to reveal the presence of any normal or altered replicative forms of C. pneumoniae, including AB. One conclusion would be that there are indeed no AB to be found in any of these tissue specimens or patients, and that a larger group of patients would need to be examined. However, this would go against the theory of a relatively high prevalence of AB participating in the atherogenic response in within smooth muscle cells, macrophages or fibroblasts, were described in a previous study (10) on atherosclerotic tissue from five patients seeking heart transplantation. The absence of typical chlamydial inclusions and their developmental forms (elementary and reticulate bodies) and the presence of necrotic cellular debris mixed with lipids and calcified material made it demanding to screen TEM sections and limits the screening for chlamydial structures by TEM and IMG.
Admittedly, one ultra-thin section only reveals a very small area of the entire atheroma, leaving many areas of the atheroma unscreened. A thorough investigation of the whole complete area of the coronary artery specimens was not possible in this study due to time and cost restraints. showed reactivity to the hypothetical protein CpB0704 that was previously described to have unaltered seroreactivity among persistently infected patients (16). Generating antibodies against
RpoA and DnaK for their use in IHC on atheromatous tissues is planned for comparative studies on tissues and serum samples.
Conclusion
In summary, the various antigens of persistent C. pneumoniae infection found in atheromatous lesions in this study could potentially be used as markers to detect such infections. Some of these may be virulence factors or immunogens specific to C. pneumoniae, thus serving as target molecules for diagnostic use or therapeutic intervention. 
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